Literature DB >> 28165633

Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study.

Seán O Hynes1, Helen G Coleman2, Paul J Kelly1,3, Steven Irwin3, Roisin F O'Neill2, Ronan T Gray2, Claire McGready1, Philip D Dunne1, Stephen McQuaid1,3,4, Jacqueline A James1,3,4, Manuel Salto-Tellez1,3, Maurice B Loughrey1,3.   

Abstract

AIMS: Both morphological and molecular approaches have highlighted the biological and prognostic importance of the tumour microenvironment in colorectal cancer (CRC). Despite this, microscopic assessment of the tumour microenvironment has not been adopted into routine practice. The study aim was to identify those tumour microenvironmental features that are most likely to provide prognostic information and be feasible to use in routine pathology reporting practice. METHODS AND
RESULTS: On the basis of existing evidence, we selected specific morphological features relating to peritumoral inflammatory and stromal responses, agreed criteria for scoring, and assessed these in representative haematoxylin and eosin (H&E)-stained whole tumour sections from a population-based cohort of 445 stage II/III colon cancer cases. Moderate/severe peritumoral diffuse lymphoid inflammation and Crohn's disease-like reaction were associated with significantly reduced risks of CRC-specific death [adjusted hazard ratio (HR) 0.48, 95% confidence interval (CI) 0.31-0.76, and HR 0.60, 95% CI 0.42-0.84, respectively]. The presence of >50% tumour stromal percentage, as assessed by global evaluation of tumour area, was associated with a significantly increased risk of CRC-specific death (HR 1.60 95% CI 1.06-2.41). A composite 'fibroinflammatory score' (0-3), combining dichotomized scores of these three features, showed a highly significant association with survival outcomes. Those with a score of ≥2 had an almost 2.5-fold increased risk of CRC-specific death (HR 2.44, 95% CI 1.56-3.81) as compared with those scoring zero. These associations were stronger in microsatellite instability (MSI)-high tumours, potentially identifying a subset of MSI-high colon cancers that lack characteristic morphological features and have an associated worse prognosis.
CONCLUSIONS: In summary, reporting on H&E staining of selected microscopic features of the tumour microenvironment, independently or in combination, offers valuable prognostic information in stage II/III colon cancer, and may allow morphological correlation with developing molecular classifications of prognostic and predictive relevance.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  colorectal cancer; inflammation; prognosis; stroma; survival

Mesh:

Year:  2017        PMID: 28165633     DOI: 10.1111/his.13181

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  14 in total

1.  Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data.

Authors:  Natalie C Fisher; Ryan M Byrne; Nigel B Jamieson; Philip D Dunne; Holly Leslie; Colin Wood; Assya Legrini; Andrew J Cameron; Baharak Ahmaderaghi; Shania M Corry; Sudhir B Malla; Raheleh Amirkhah; Aoife J McCooey; Emily Rogan; Keara L Redmond; Svetlana Sakhnevych; Enric Domingo; James Jackson; Maurice B Loughrey; Simon Leedham; Tim Maughan; Mark Lawler; Owen J Sansom; Felicity Lamrock; Viktor H Koelzer
Journal:  Clin Cancer Res       Date:  2022-09-15       Impact factor: 13.801

2.  Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma.

Authors:  K M H Vangangelt; G W van Pelt; C C Engels; H Putter; G J Liefers; V T H B M Smit; R A E M Tollenaar; P J K Kuppen; W E Mesker
Journal:  Breast Cancer Res Treat       Date:  2017-12-22       Impact factor: 4.872

Review 3.  Mechanistic Insights into Colorectal Cancer Phenomics from Fundamental and Organotypic Model Studies.

Authors:  Frederick C Campbell; Maurice Bernard Loughrey; Jane McClements; Ravi Kiran Deevi; Arman Javadi; Lisa Rainey
Journal:  Am J Pathol       Date:  2018-07-18       Impact factor: 4.307

4.  The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study.

Authors:  Ann Christina Eriksen; Flemming B Sørensen; Jan Lindebjerg; Henrik Hager; René dePont Christensen; Sanne Kjær-Frifeldt; Torben F Hansen
Journal:  Int J Colorectal Dis       Date:  2018-05-21       Impact factor: 2.571

5.  Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study.

Authors:  Marloes Smit; Gabi van Pelt; Annet Roodvoets; Elma Meershoek-Klein Kranenbarg; Hein Putter; Rob Tollenaar; J Han van Krieken; Wilma Mesker
Journal:  JMIR Res Protoc       Date:  2019-06-14

6.  Fusobacterium nucleatum tumor DNA levels are associated with survival in colorectal cancer patients.

Authors:  Andrew T Kunzmann; Marcela Alcântara Proença; Haydee Wt Jordao; Katerina Jiraskova; Michaela Schneiderova; Miroslav Levy; Václav Liska; Tomas Buchler; Ludmila Vodickova; Veronika Vymetalkova; Ana Elizabete Silva; Pavel Vodicka; David J Hughes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-07-31       Impact factor: 3.267

7.  Preoperative, biopsy-based assessment of the tumour microenvironment in patients with primary operable colorectal cancer.

Authors:  James H Park; Hester van Wyk; Donald C McMillan; Joanne Edwards; Clare Orange; Paul G Horgan; Campbell Sd Roxburgh
Journal:  J Pathol Clin Res       Date:  2019-10-14

8.  Does heterogeneity matter in the estimation of tumour budding and tumour stroma ratio in colon cancer?

Authors:  Ann C Eriksen; Johnnie B Andersen; Jan Lindebjerg; René dePont Christensen; Torben F Hansen; Sanne Kjær-Frifeldt; Flemming B Sørensen
Journal:  Diagn Pathol       Date:  2018-03-20       Impact factor: 2.644

9.  Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer.

Authors:  Stéphanie M Zunder; Gabi W van Pelt; Hans J Gelderblom; Christoph Mancao; Hein Putter; Rob A Tollenaar; Wilma E Mesker
Journal:  Br J Cancer       Date:  2018-05-14       Impact factor: 7.640

Review 10.  The Crohn's-Like Lymphoid Reaction to Colorectal Cancer-Tertiary Lymphoid Structures With Immunologic and Potentially Therapeutic Relevance in Colorectal Cancer.

Authors:  Asaf Maoz; Michael Dennis; Joel K Greenson
Journal:  Front Immunol       Date:  2019-08-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.